St. Jude Medical Announces TOCCASTAR Clinical Trial Meets Primary Safety And Efficacy Endpoints At Heart Rhythm 2014

Published: May 08, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced results of the TOCCASTAR clinical trial at Heart Rhythm 2014, the Heart Rhythm Society’s 35th Annual Scientific Sessions in San Francisco. Results from the first prospective, randomized study of contact-force ablation technology for the treatment of paroxysmal atrial fibrillation (AF) met primary endpoints and supplement the growing body of evidence that supports the safety and effectiveness of contact-force ablation technology.

Help employers find you! Check out all the jobs and post your resume.

Back to news